CLPT stock forecast, quote, news & analysis
ClearPoint Neuro Inc is a commercial-stage medical device company that develops and commercializes integrated systems used in minimally invasive neurosurgical procedures in the brain... Show more
Why ClearPoint Neuro (CLPT) Stock Is Down -22.9% in the Last 30 Days
Key Takeaways
- ClearPoint Neuro (CLPT) shares declined approximately 22.9% over the past 30 days, retreating from $18.48 on June 26 to $14.24 as of July 28, erasing much of the stock's explosive mid-June rally.
- The sell-off reversed a sharp but unsustainable 47% intraday spike on June 17 that was driven by thin volume and speculative momentum rather than fundamental catalysts.
- Over the broader quarter, CLPT remains up approximately 28.5%, supported by strong Q1 2026 earnings with 43% year-over-year revenue growth and multiple regulatory milestones.
- Insider selling — including the CEO's sale of 60,000 shares at $17.79 — combined with a Weiss Ratings "Sell" reiteration and pre-earnings uncertainty weighed heavily on sentiment.
- The upcoming Q2 2026 earnings release on August 3 represents a pivotal near-term catalyst for the stock.
ClearPoint Neuro (CLPT) Company Overview and Market Position
ClearPoint Neuro, Inc. is a commercial-stage medical device company specializing in precise navigation systems for minimally invasive neurosurgical procedures in the brain and spine. Its flagship product, the ClearPoint Neuro Navigation System, enables surgeons to perform MRI-guided interventions with submillimeter precision. The company also offers the IRRAflow active fluid exchange platform, the Prism Neuro laser therapy system, and the SmartFlow cannula for convection-enhanced gene therapy delivery. ClearPoint partners with over 60 biopharmaceutical companies and supports more than 25 clinical trials across 15 disease indications. With more than 175 active global centers using its technology, the company operates across four growth pillars: Biologics and Drug Delivery, Neurosurgery Navigation, Laser Therapy and Access, and Neurocritical Care.
ClearPoint Neuro (CLPT) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, CLPT shares have fallen approximately 22.9%, declining from a closing price of $18.48 on June 26 to $14.24 by July 28. The decline was characterized by a steady erosion of value across nearly every trading session in July, with particularly sharp drops on July 13 (-5.7%), July 16 (-3.9%), and July 23 (-3.6%). Trading volume during the sell-off remained elevated relative to pre-June levels, suggesting meaningful distribution rather than a low-liquidity drift.
Contrasting this short-term weakness, the stock remains solidly in positive territory over the broader quarter. From approximately $11.08 on April 28 to the current $14.24, CLPT has gained roughly 28.5%. The quarterly performance was anchored by the company's Q1 2026 earnings release in mid-May, which showed record revenue of $12.1 million, 43% overall growth, and gross margin expansion to 64%. The quarter also included the June 17 parabolic surge that briefly sent shares above $20 intraday before the current correction took hold.
What Drove CLPT Stock Price in the Last 30 Days
The defining event shaping CLPT's 30-day performance was the aftermath of the June 17 trading anomaly. On that day, the stock exploded approximately 47% intraday on volume of roughly 6.9 million shares — more than 12 times the 20-day average. According to multiple market data sources, the move occurred on critically thin pre-market volume with a Z-score of -1.4, indicating a liquidity-driven breakout rather than one backed by broad institutional participation. The stock printed an intraday high of approximately $20.50 before settling back to close at $16.81.
In the sessions that followed, the stock continued grinding higher to $19.43 by June 29, buoyed by a B. Riley analyst upgrade that lifted the price target from $20 to $30. However, the rally lacked staying power. CEO Joseph Burnett sold 60,000 shares at $17.79 on June 17, part of over 108,000 insider shares sold during the prior 90 days. This insider activity, coupled with the thin-volume nature of the breakout, eroded confidence. On July 17, Weiss Ratings reiterated a "Sell (D-)" rating on CLPT, adding further downward pressure. By the third week of July, the stock had given back nearly all of the post-spike gains as traders de-risked ahead of the August 3 Q2 earnings release. Broader small-cap medtech rotation and ongoing cash burn concerns — the company held $35.6 million in cash as of March 31 — contributed to the sell-off.
What Drove CLPT Stock Performance Over the Last Quarter
Despite the sharp 30-day reversal, CLPT's quarterly performance tells a more constructive story. The stock's climb from the $11 range in late April to its mid-June highs was fueled by tangible operational progress. The Q1 2026 earnings release on May 13 exceeded revenue expectations at $12.1 million, driven by 80% growth in neurosurgery navigation revenue and a 177% surge in capital equipment and software sales. Gross margins expanded to 64%, and management reaffirmed full-year 2026 revenue guidance of $52 million to $56 million.
Additional quarterly catalysts included FDA clearance and the first clinical use of the Velocity Alpha MR High Speed Surgical Drill System, receipt of a Medical Device License from Health Canada for the ClearPoint Neuro Navigation System, and the company's announcement of plans to enter the focused ultrasound market. The June 17 spike — however technically fragile — reflected genuine investor enthusiasm around ClearPoint's diversified neurotechnology pipeline and its exposure to the cell and gene therapy revolution. The stock's subsequent pullback does not negate these fundamental advancements but rather highlights the risk of overextension following a low-volume parabolic move.
Trending AI Robots
In volatile market environments like the one currently affecting ClearPoint Neuro, traders often look beyond traditional analysis to identify opportunities. Tickeron's Trending AI Robots page offers a curated selection of AI-powered trading bots designed to navigate thousands of tickers across diverse market conditions. With hundreds of bots available, Tickeron highlights only the top-performing and most relevant strategies — each varying by trading style, timeframe, and performance metrics. Whether focused on short-term momentum or longer-term trend following, these AI-driven tools provide an additional layer of analysis for traders seeking to cut through market noise. Explore the Trending AI Robots section to see which strategies are currently leading.
CLPT Stock Forecast Drivers: What Investors Should Watch Next
The most immediate catalyst for CLPT is the Q2 2026 earnings report scheduled for August 3, 2026. Analysts expect revenue of approximately $12.73 million and a loss of $0.27 per share. Investors will scrutinize IRRAflow integration progress, sequential revenue growth, and any updates to full-year guidance. Cash burn trajectory remains critical; management has stated it expects cost synergies from the IRRAS acquisition to reduce cash burn in the second half of 2026.
Beyond earnings, several factors merit attention: the pace of ClearPoint Advanced Laboratories facility buildout and its impact on preclinical service revenue; progress with the focused ultrasound prototype; the UCB acquisition of Neurona Therapeutics — a ClearPoint partner — and its implications for the pivotal Phase III trial; and broader FDA regulatory dynamics affecting both the device and biologics sides of the business. With analyst price targets ranging from $16 (Stifel) to $30 (B. Riley), and a consensus Hold rating, the dispersion in expectations underscores the stock's binary risk-reward profile heading into the second half of 2026.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for CLPT turns positive, indicating new upward trend
CLPT saw its Momentum Indicator move above the 0 level on August 11, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 100 similar instances where the indicator turned positive. In of the 100 cases, the stock moved higher in the following days. The odds of a move higher are at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for CLPT just turned positive on August 11, 2026. Looking at past instances where CLPT's MACD turned positive, the stock continued to rise in of 55 cases over the following month. The odds of a continued upward trend are .
The 50-day moving average for CLPT moved above the 200-day moving average on July 22, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CLPT advanced for three days, in of 267 cases, the price rose further within the following month. The odds of a continued upward trend are .
CLPT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
CLPT moved below its 50-day moving average on August 04, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CLPT crossed bearishly below the 50-day moving average on July 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLPT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for CLPT entered a downward trend on August 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CLPT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CLPT's P/B Ratio (43.478) is slightly higher than the industry average of (11.008). P/E Ratio (0.000) is within average values for comparable stocks, (71.361). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.985). CLPT has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.017). P/S Ratio (10.616) is also within normal values, averaging (31.171).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLPT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company, which engages in the development and commercialization of innovative platforms for performing minimally invasive surgical procedures in the brain and heart.
Industry MedicalNursingServices